Actuate Therapeutics (ACTU) Income from Continuing Operations (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Income from Continuing Operations of 4604660.0 for Q4 2025, up 27.92% year-over-year from 3599502.63 in Q4 2024, and up 14.85% quarter-over-quarter from 5407470.0 in Q3 2025.
Actuate Therapeutics (ACTU) Income from Continuing Operations (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Income from Continuing Operations for 3 consecutive years, with 4604660.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 27.92% year-over-year to 4604660.0; the TTM figure through Dec 2025 stood at 22278559.0 (up 10.53% YoY), while the FY2025 annual figure was 23875037.0, up 61.89% from the prior year.
- Income from Continuing Operations climbed to 4604660.0 in Q4 2025 per ACTU's latest filing, from 5407470.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4604660.0 in Q4 2025 and bottomed at 7763544.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 6062104.82 across 3 years, with a median of 5949405.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 27.92% in 2025 and fell as far as 9.53% in 2025.
- Actuate Therapeutics' Income from Continuing Operations stood at 7560556.0 in 2023, then advanced by 15.5% to 6388697.0 in 2024, then grew by 27.92% to 4604660.0 in 2025.
- Business Quant data shows ACTU's Income from Continuing Operations at 4604660.0 in Q4 2025, 5407470.0 in Q3 2025, and 5949405.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | -4.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.60 Mn |
| Sep 30, 2025 | -5.41 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Mar 31, 2025 | -6.32 Mn |
| Dec 31, 2024 | -6.39 Mn |
| Sep 30, 2024 | -5.32 Mn |
| Jun 30, 2024 | -5.43 Mn |
| Mar 31, 2024 | -7.76 Mn |
| Dec 31, 2023 | -7.56 Mn |
| Sep 30, 2023 | -6.35 Mn |
| Jun 30, 2023 | -5.59 Mn |